Duncan Williams Asset Management LLC Buys 324 Shares of Amgen Inc. (NASDAQ:AMGN)

Duncan Williams Asset Management LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 14.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,619 shares of the medical research company’s stock after acquiring an additional 324 shares during the quarter. Duncan Williams Asset Management LLC’s holdings in Amgen were worth $683,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capital Performance Advisors LLP bought a new position in Amgen in the 3rd quarter valued at $25,000. Hershey Financial Advisers LLC bought a new stake in Amgen during the second quarter valued at $30,000. Legacy Investment Solutions LLC purchased a new position in Amgen during the third quarter worth about $29,000. Matrix Trust Co bought a new position in Amgen in the 3rd quarter worth about $36,000. Finally, Livelsberger Financial Advisory bought a new position in Amgen in the 3rd quarter worth about $56,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Barclays boosted their price objective on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Citigroup decreased their price target on shares of Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Leerink Partners dropped their price objective on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft reduced their target price on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Finally, Piper Sandler Companies reiterated an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $314.65.

Amgen Trading Down 0.9 %

AMGN opened at $275.42 on Friday. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The business has a 50 day simple moving average of $271.39 and a two-hundred day simple moving average of $305.99. The firm has a market capitalization of $148.05 billion, a price-to-earnings ratio of 35.27, a PEG ratio of 2.78 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.96 earnings per share. Analysts predict that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.46%. Amgen’s payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.